4SC’s Experimental Hodgkin’s Lymphoma Drug Awarded Orphan Status

4SC AG (VSC) said U.S. regulators granted orphan drug status to the experimental Hodgkin’s Lymhoma drug Resminostat.

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.